CA-CODED-AGENCY
14.4.2021 16:02:07 CEST | Business Wire | Press release
Global modern communications company Coded Agency today announces a highly-anticipated, strategic overhaul of its branding and website following steady growth and innovation into new markets and industries.
Coded Agency, formerly known as codedpr, was founded in 2015 and quickly grew to become a leading agency of record for a range of lifestyle, fashion, beauty, fitness and wellness brands. In 2020, the agency generated a net income increase of 35%, despite an unprecedented global pandemic. Its upward trajectory continues in 2021 with not only a 65% increase in revenue in Q1 and a 50% increase in clients between Q1 and Q2, but a bold, fresh new look, instrumental employee promotions and expansion into Europe with the agency founder’s relocation to France.
The minority-owned, female-founded company renews its namesake as Coded Agency in tandem with a new website and branding designed by Designsake Studio, a San Francisco-based, award-winning and female founded design firm. “Coded Agency gets what it takes to build and support modern brands and we’re proud of our partnership with this women-owned and operated agency,” said Danielle McWaters, Founder & CCO of Designsake Studio.
Reflecting expansion into a more modern approach to communications that extends beyond traditional public relations and standard influencer programming, the new branding and positioning underscores the agency’s abilities to meet the evolving needs of its clients in a fast-changing world. The new website highlights the agency’s broad range of services including PR, influencer and celebrity marketing, event activations, partnerships and endorsements.
“Our goal for the redesign was to create a new brand identity that enhanced the visitor’s digital experience and showcased the results they deliver for their clients,” McWaters explained. “A fresh color palette, eye-catching typography and monochromatic photography communicate the agency’s tailored, edgy and purposeful approach to communications strategy,” McWaters continued.
Coded Agency prides itself on working with purposeful brands that embrace diversity, sustainability, inclusivity and female empowerment, aiming to amplify their stories. Most recently, Coded Agency has partnered with MVMT , premium watches and accessories; Scentbird , luxury fragrance subscription service; and niLuu , sustainably-made, PETA-approved vegan silk loungewear and sleep accessories, among other client wins. In addition, the agency is honored to continue ongoing partnerships with loyal clientele: Alleyoop , beauty and lifestyle brand; Vitality Institute , renowned beauty and wellness brand known for its chemical peel and medical-grade skincare products; and Caleres brands Allen Edmonds, Naturalizer and Blowfish Malibu.
“To meet the agency’s ongoing plans for growth, we have expanded key roles internally and are establishing a global presence with full-time team members located in Los Angeles, New York and France,” said Jennifer Wentzo, Coded Agency’s Founder and CEO. “Synergistic alignment with companies such as our existing client base and partners like Designsake Studio is part of our DNA. We are proud of our redesign and hope it reflects our forward-thinking approach to modern communications.”
Recent promotions include Jules Barker, appointed Vice President from Senior Director, and Jamie Hecht, named New York PR Manager from Senior Account Executive. In their new roles, they will manage agency operations, continue to foster team development, oversee the agency’s diverse client roster and spearhead the agency’s business development and East Coast representation, respectively.
About Coded Agency
Founded in 2015, Coded Agency is a modern, full-service marketing communications agency situated at the intersection of strategy, instinct and hustle. From dynamic startups to legacy brands under publicly traded parent companies in a diverse range of industries, the agency team delivers impactful, meaningful campaigns that help its brands grow. Consistently topping seven figures in annual revenue since 2016, the team dreams about what’s on the horizon while keeping an eye on the bottom line and infuses their work with the passion and dedication that is singular to the entrepreneurial spirit. For more information, visit www.codedagency.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom